Abstract: Osteoarthritis (OA) is the leading cause of joint pain and disability in middle-aged and elderly patients, and is characterized by progressive loss of articular cartilage that eventually leads to a complex process involving degradation of various components of the cartilage matrix, chief among them are the cartilage-specific type II collagen (CII) and aggrecan. While the loss of aggrecan is thought to be an early and reversible process, degradation of CII is considered to be irreversible and a key step in the loss of structural and functional integrity of cartilage. Among the various matrix metalloproteinases (MMPs), MMP-13 is specifically expressed in the cartilage of human OA patients and is not present in normal adult cartilage. It is the major collagenase in OA cartilage and has the highest activity against CII. However, the clinical utility of broad-spectrum MMP inhibitors developed for treatment of OA has been restricted by dose-and duration-dependent musculoskeletal side effects in humans. Consequently, selectively inhibiting the MMP-13 would seem to be an attractive therapeutic objective. This review mainly focuses on selective MMP-13 inhibitors development in terms of OA since the late 90s, in terms of synthetic compounds of low molecular mass incorporating specific zinc-binding groups, non-zinc-binding groups. In addition, dual inhibitors of MMP-13 and aggrecanase are also reviewed. Special emphasis is placed on logistic concerns for lead compound search as well as the structure-activity relationship (SAR) in this field. Through these methods, new hope is emerging for the treatment of OA through selective inhibition of MMP-13.
INTRODUCTION
Osteoarthritis (OA), the most prevalent form of arthritis, is one of the most frequent health problems in middle-aged and elderly people [1] , approximately 80% of individuals older than age 65 years have some form of OA [2] . With the world's population ageing, the incidence of OA is rapidly increasing, posing serious medical and social problems [3] , patients with OA suffer from cartilage degeneration resulting in loss of joint function.
Despite significant social demand for more information, risk factors of this disease identified by epidemiologic studies to date have been limited to age, obesity, trauma history, occupation and gender, these factors are closely related to the accumulation of mechanical stress to joints. Research has demonstrated that the main features of OA are cartilage damage, subchondral bone remodeling, joint space narrowing, synovial inflammation, and osteophyte formation at the joint margins. Regardless of the initial trigger, cartilage damage is the hallmark of OA. Current treatments are limited to symptomatic relief with analgesics, nonsteroidal antiinflammatory drugs (NSAIDs), intra-articular injections of hyaluronic acid conjugates (Synvisc) or surgical joint replacement [4, 5] . The efficacy of nutritional supplements (glucosamine and chondroitin sulfate) is somewhat controversial, and there are currently no treatments available that retard or reverse the gradual destruction of cartilage associated with the disease [6] [7] [8] . Because these methods do not protect the articular cartilage or delay disease progression, allowing the disease to progress into irreversible extracellular matrix (ECM) loss and chronic disability, therefore, there is a great interest in identifying and characterizing the proteases responsible for cartilage degradation as potential targets in developing therapeutics to prevent joint destruction in OA.
The ECM is composed of structural components such as collagens, proteoglycans and glycoproteins which provide a scaffold within which cells reside. During normal physiological processes such as embryonic development and growth, tissue remodelling and repair, ovulation, blastocyst implantation, apoptosis, angiogenesis *Address correspondence to this author at the Jiangsu Key Laboratory for TCM Formulae Research, Nanjing University of Chinese Medicine, 138 Xianlin Road, 210046, Nanjing, Jiangsu, P.R. China; Tel/Fax: +86-25-85811916; E-mails: yupingtang@njutcm.edu.cn; dja@njutcm.edu.cn † Co-First Authors.
and organ morphogenesis, the ECM must be degraded and tissue remodelled [9] . In normal adult tissue, joint cartilage is constituted of a framework of CII [10] [11] [12] , in which proteoglycans are connected to hyaluronic acid and waves smoothly. Because proteoglycans contain a large quantity of water, they provide elasticity and lubricity to the joint surface. However, in the OA cartilage, most of the proteoglycans are cut, fragmented, and floating in the synovial fluid. Due to the loss of the shock-absorber, the mechanical stress is loaded directly onto collagen, which is also cut and degraded. Collagen is a triple helical protein that is resistant to most proteases but is efficiently recognized and degraded by collagenase 3, known as matrix metalloproteinase-13 (MMP-13). MMP-13 catalyzes the hydrolysis of CII at a unique site resulting in 3/4-and 1/4-length polypeptide products. This enzyme belongs to a family of enzymes termed matrix metalloproteinases (MMPs) [13] , which are zincdependent endopeptidases involved in the remodeling of extracellular matrix proteins. MMP-13 is not found in normal adult tissues but is expressed in the joints and articular cartilage of osteoarthritis patients [14] . Furthermore, a MMP inhibitor that preferentially inhibits MMP-13 has been shown to block the degradation of explanted human osteoarthritic cartilage [15] . On the basis of these findings, synthetic MMP-13 inhibitors are being sought as potential therapeutic agents to prevent cartilage degradation and to slow down the progression of OA [12] . Unfortunately, few MMP inhibitors (MMPIs) have been examined in clinical trials for OA and none have been successfully utilized as therapeutic agents so far. In fact, many broad spectrum MMPIs have been found to display a dose-limiting toxicity in the form of musculoskeletal side effects including joint stiffness and inflammation [16] . Although the human joint side effects are reversible upon withdrawal of the drug, musculoskeletal syndrome (MSS) characterized by joint stiffness and pain, particularly in the hands and shoulders [17] , has halted clinical trials of many nonselective MMPIs. Possible reasons for the low success rate of MMPIs in the clinic are mainly from unwanted side effects caused by their lack of selectivity, since inhibition of MMP-1 may be responsible for the musculoskeletal side effects observed clinically with broad-spectrum inhibitors. However, the postulate that MMP-1 inhibition alone is responsible for the side effects was dispelled by clinical trials with CP-544439 ( Fig. 1) , a hydroxamic acid-based MMP-13 inhibitor that spared MMP-1 but which was otherwise non-selective [18] . This compound still produced MSS despite its lack of activity versus MMP-1. MMP-14 inhibition has also been proposed to cause MSS [19] , but this idea has not yet been clinically evaluated. Others have speculated that sheddase inhibition, specifically inhibition of tumor necrosis factor-converting enzyme (TACE) [20] [21] [22] [23] [24] , could be responsible for the observed side effects. The underlying mechanisms may possibly be mediated through the failure to downregulate receptor signaling by proteolytic release of the extracellular domain [25] .
Therefore, trying to reduce the MSS is an important therapeutic consideration when treating OA. Hence, pharmaceutical research has mainly focused on the discovery of potent inhibitors of MMP-13 displaying a high degree of selectivity over other MMPs. This review mainly focuses on selective MMP-13 inhibitors development in terms of OA since the late 90s, in terms of synthetic compounds of low molecular mass incorporating specific zinc-binding groups, non-zinc-binding groups. In addition, dual inhibitors of MMP-13 and aggrecanase are also reviewed. Special emphasis is placed on logistic concerns for lead compound search as well as the structure-activity relationship (SAR) in this field. Through these methods, new hope is emerging for the treatment of OA through selective inhibition of MMP-13.
METHODS IN DESIGN OF MMPIS
The design and synthesis of MMPIs continue to be a prominent area of pharmaceutical research. Rapid advances in all aspects of the drug discovery process have energized these research efforts, and resulted in the introduction of a number of small molecules of diverse structural make-up into clinical trials or advanced preclinical status.
An early approach for the identification of MMPIs has been the design of peptide and peptide-like compounds [13, 26] , combing backbone features (P1, P1 , P2 , P3 regions) which would favorably interact with the enzyme subsites (S1, S1 , S2 , S3 pockets) and functionality capable of binding zinc (chelator) in the catalytic site (Fig. 2) . Following a substrate-based approach, early MMPIs were designed to mimic natural substrates of MMPs by using a short peptide derivative attached to a zinc-binding group.
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Enzyme Subsites Fig. (2) . Design of peptide-based MMPIs.
However, clinical trials of these early peptide-based MMPIs giving disappointing results have led to intensive discussions on how to conquer the drawbacks of broad-spectrum MMPIs, and gain new classes of inhibitors characterized by improved potency and, above all, high selectivity against the specific MMP subtypes involved in the targeted pathology in order to minimize side effects [27] . To achieve this goal, the MMPI field has evolved to focus on nonpeptide inhibitors, that are selective and orally active with good duration of action, and two possible strategies in new compound design can be seen.
The first is the design of sub-type selective MMPIs, by optimizing the interactions between the inhibitors and the enzyme to achieve improved potency. Based on this point, to dig out more specific MMPIs, Whittaker M et al. offered some useful clues, they stated that an effective MMPI requires a zinc binding group (ZBG) as functional group capable of chelating the active site zinc (II) ion, at least one functional group which provides a hydrogen bond interaction with the enzyme backbone, and one or more substrate-like side chains which undergo effective van der Waals interactions with one of the subsites of the enzyme active sites, such as S1 and S2 pockets [28] . This approach is, undoubtedly, still the most popular method to date to obtain potent MMPIs. Early typically identified ZBGs include hydroxamate, reversed hydroxamate, thiolate, phosphinate, carboxylate, phosphonate, this is followed by the derivatives of these ZBGs, such as hydrazide, sulfonylhydrazide, Nhydroxyurea, mercaptosulfide, etc, and the newly exploited nitrogen-based ZBGs, heterocyclic bidentate ZBGs [29] . Now, the new challenges include the development of new allosteric non-zinc binding inhibitors, devoid of ZBGs [30] .
The second is the use of MMP structures as a basis for inhibitor design. In fact, the increasing availability of high resolution X-ray crystal structures for many members of this protein family makes MMPs ideally suited for structure based design approaches, which are now routinely used in this area. Most of the currently available 3D structures for some MMP family members are presented as the complexes of the catalytic MMP domains with various known peptidic, peptidomimetic, or non-peptidic inhibitors. These structures enable the structure-based drug design and improvement of highaffinity ligands, which might be elaborated into potential drugs [31] [32] [33] . Besides, the availability of combinatorial chemistry and computational resources, as well as the QSAR studies by using COMFA, GRID and CoMSIA approaches has accelerated the inhibitors development. All these studies provide useful information in elucidating the mechanisms of chemical-biological interactions for certain MMPs.
SELECTIVE MMP-13 INHIBITORS
In the past few years, some potent 'broad spectrum' MMPIs have been proposed and tested against OA [34] . Some of them have entered clinical trials, but at present none of them is on the market. Compounds such as, CGS-27023A (Fig. 3) , has shown a severe MSS, with fibroproliferative effects in the joint capsule of the knees [17] . These effects are thought to be linked to an impairment of normal tissue remodeling governed by the MMP-1 and/or by sheddases such as TACE [17] . Considering these data, many efforts were directed to develop a more selective second generation of inhibitors against the specific MMP-13 believed to be involved in the pathologies of OA since the late 90s. The MMP-13 inhibitors discussed will be categorized according to the nature of group used to binds the active site metal ion. Based on this premise, the selective MMP-13 inhibitors can be broadly categorized into seven groups: hydroxamic acids, carboxylic acids, phosphorus, -fluorinated ketone, thiols, pyrimidinetrione and non-Zinc-chelating-based MMP-13 inhibitors.
Hydroxamic Acid-Based MMP-13 Inhibitors
The hydroxamic acid group is overwhelmingly the most commonly used ZBG in inhibitor design and is generally found to be the most effective. Hydroxamic acid bind the catalytic zinc (II) ion in a bidentate fashion, blocking substrate access to the active site and rendering the metal incapable of peptide hydrolysis. With the advent of structure based design, MMP-13 inhibitors have been further modified in an effort to obtain greater specificity and potency.
In 2000, Chen's group used the high-resolution NMR solution structure of the catalytic fragment of MMP-13 [35] as a starting point for structure-based design of selective inhibitors for MMP-13 (Fig. 4) . The major structural difference observed between the MMP structures was the relative size and shape of the S1 pocket where this pocket was significantly longer for MMP-13, nearly reaching the surface of the protein. On the basis of the extended nature of the MMP-13 S1 pocket, an inhibitor potent and selective for MMP-13 was designed from an initial high throughput screening (HTS) lead. CL-82198 was identified as a weak (10 μM) inhibitor against MMP-13 while demonstrated no activity against MMP-1, MMP-9, or the related enzyme TACE. The drug-like properties of CL-82198 made it an ideal candidate for optimization of enzyme potency and selectivity. On the basis of NMR binding studies, it was shown that inhibitor CL-82198 bound within the entire S1 pocket of MMP-13 which was the basis of its selectivity against MMP-1, MMP-9, and TACE. A strategy utilizing this information was devised for designing new inhibitors that showed enhanced selectivity toward MMP-13. Their design strategy combined the critical selectivity features of CL-82198 with the known potency features of a nonspecific MMP inhibitor (WAY-152177, 82 nM for MMP-1, 21 nM for MMP-9, 15 nM for MMP-13, 240 nM for TACE), to generate a potent and selective MMP-13 inhibitor (WAY-170523). WAY-170523 had an IC 50 of 17 nM for MMP-13 and showed >5800-, 56-, and >500-fold selectivity against MMP-1, MMP-9, and TACE, respectively.
Recently, a new generation of cyclic MMP-13 inhibitors 1 (Table 1) derived from d,l-piperazinecarboxylic acid [36] has been described by Cheng et al., their design involved incorporation of a hydroxamic acid as the bidentate chelating agent for the catalytic zinc, placement of a sulfonamide group at the 1N-position of the piperazine ring (see CGS-27023A) [37] to fill the S1 pocket of the enzyme, and finally, attachment of diverse functional groups (i.e., N-alkyl, sulfonamide, carbamate, and amide) at the 4N-position to optimize potency and oral absorption. Representative example was provided by the structure 1-1, which was surprisingly selective for MMP-13.
Although a substantial number of nonpeptide sulfonamide hydroxamate MMPIs have been studied, almost all of these compounds (such as CGS-27023A) [37] have been derived fromamino acids, with a single carbon linking the sulfonamide nitrogen and the zinc chelating hydroxamic acid moiety [38, 39] . Rencently, Levin et al. were interested in ascertaining whether novel, potent MMPIs 2 [40] ( Table 1 ) could be made by using an aromatic ring as the linker between the sulfonamide nitrogen and the hydroxamate. Through this method, the 3-methyl derivative 2-1 was in particular less than 10nM against both MMP-9 and MMP-13. Structural analysis by NMR of the solution structure of compound 2-1 bound in the active site of MMP-13 indicated that the paramethoxyphenyl group lies in the S1 pocket of the enzyme, and that the pyridine ring was solvent exposed [41] . The sulfonyl oxygens were within hydrogen bonding distance to the peptide backbone, and the anthranilate aromatic ring occupied the S2 pocket of the active site. Evaluation of 2-1 in an in vivo rat sponge-wrapped cartilage model [42] demonstrated that the administration of 50mg/kg/day ip of 6e via osmotic pump gave a 51% inhibition of collagen degradation. Table 1) , for the S1 pocket of the MMPs and TACE is the "specificity" pocket wherein the most dramatic structural differences between the enzymes lies, P1 groups lengthier than the para-methoxyphenyl were required to take advantage of this region of the enzymes [44] . Pyridyl ether 3-1, a potent MMP-9 and MMP-13 inhibitor with greater than 800-fold selectivity over MMP-1, has also demonstrated significant inhibition of collagen degradation in a rat sponge-wrapped cartilage model. Oral dosing at 50 mg/kg/bid provided a 35% inhibition (n=2) of collagen degradation compared to a 51% inhibition by CGS-27023A at the same dose. Since the oral activity of aryl hydroxmates was greatly enhanced by the incorporation of a basic amine moiety into the inhibitor molecule, a similar circumstance has been reported for the sulfonamide-hydroxamates, exemplified by the oncology clinical candidate CGS-27023A [37] . So Levin et al. reported on the synthesis and evaluation of a series of anthranilate hydroxamates [45] , of general structure 4 (Table 1), containing basic amine groups at R2 or R3 in the pursuit of an orally active therapeutic agent. Analysis of NMR and molecular modeling studies of anthranilate hydroxamates in the active site of MMP-13 suggested that polar functionality on the sulfonamide nitrogen and at the anthranilate 3-position would be solvent exposed [41, 46] . Activity could be increased further by using a biaryl ether P1 group in conjunction with the piperazine substituent on the anthranilate phenyl ring. Thus, pchlorophenyl ether 4-1 was greater than 100-fold selective for both MMP-9 and MMP-13 and has an IC 50 of below 1 nM versus MMP-13. In the dialysis implant model, 4-1 (25 mg/kg) was 10-30% more potent than an equal dose of CGS-27023A, at a concentration of 1 mM in the cartilage explant assay. In the sponge-wrapped cartilage model, 4-1 surpassed CGS-27023A. Compound 4-1 at 50 mg/kg po bid provided a 73% inhibition of collagen degradation compared to a 55% inhibition by CGS-27023A at the same dose.
From a series of -substituted--sulphone hydroxamates 5 (Table 1) which were both MMP and phosphodiesterase inhibitors [47] discoveried by Burns et al., in 2001, Becker's group reported preliminary SAR of a series of potent -amino--sulphone hydroxamate MMP-13 inhibitors 6 that were selective in sparing MMP-1 [48] . Potency and selectivity were modulated by varying the P1 moiety (XR1), and a wide variety of substituents were tolerated in the P1 (solvent exposed) -amino position of MMP-13. This position was utilized to modulate solubility and pharmacokinetic (PK) parameters. These compounds such as 6-1 exhibited sub-nanomolar potency for MMP-13 and good selectivity versus MMP-1. When dosed orally in rats at 20 mpk to assess absorption by measuring C max , and the concentration remaining at 6 h was used as an initial rough indicator of the half-life. Compounds 6-1 showed a high C max of 6.66 μg/mL, with 0.049 μg/mL remaining at 6 h.
In the preceding paper, Becker's group reported the preparation and preliminary SAR of a series of -amino--alkyl--sulphones 7 [49] ( Table 1 ) that were highly selective in sparing MMP-1, based on the hypothesis that the MSS effect observed clinically with the broad-spectrum inhibitor marimastat [50] was due to potent inhibition of MMP-1. Alkyl substituents alpha to the hydroxamate were employed to modulate PK properties including absorption and halflife, as well as physicochemical properties, while the P1 substituent was varied to optimize potency and selectivity. The -methyl--amino analogue 7-1 was orally bioavailable and showed a high C max of 6.43 μg/mL when dosed orally in rats at 20 mpk to assess absorption, furthermore, it was less than 15 ng/mL in plasma at the 6 h time point.
In 2000, Barta's group described a novel series of aryl hydroxamic acid derivatives 8 that inhibited MMP-2 and -13 and spared MMP-1 [51] . These compounds 8 were the product of de novo design, the two oxygens of the hydroxamic acid chelated the active site zinc, the sulfonyl group was held axial to the piperidine ring and accepted a hydrogen bond from the backbone amide of Leu 160, and the piperidine moiety extended deeply into the enzyme S1 pocket. The depth to which these analogs penetrated the S1 subsite accounted for their substantial selectivity for MMP-2 and MMP-13 over MMP-1. Interestingly, the length of the P1 group and the atom connecting the distal phenyl ring to the piperidine ring were keys to obtaining potency, as MMP-1 had a relatively more shallow pocket. The most active analogues 8-1 had P1 subunits which reach down to the bottom of the pocket, showed extraordinary level of selectivity against MMP-1.
As 8-1 was dosed in rat, it was found to be orally bioavailable (C max 1230 ng/mL @ 20MPK; t 1/2 =0.8 h), in order to improve both exposure and half-life in the rat, Barta's group thought that the C max values of the compounds could be improved by synthesizing analogues with water-solubilizing groups built into the structure. Additionally, they felt they might be able to extend the half-life of compounds by increasing steric hindrance around the potentially metabolizable hydroxamate moiety [52] . X-ray crystallography [51] revealed that substituents on the W, X, and Y positions of 9 ( Table  1 ) were solvent exposed rather than pointing towards the enzyme backbone. Thus, replacing the hydrogens in these positions should not deleteriously impact enzyme potency. The W position looked particularly attractive as a substitution point that could improve t 1/2 because of its proximity to the hydroxamate, introduction of hindering groups on the 'backbone' aryl ring bearing the hydroxamate (9-1) resulted in an unexpected increase in the MMP-13 potency.
X-ray crystal structures of MMPs (including MMP-13) with bound inhibitors revealed that inhibitor binding interactions typically include coordination of the active site Zn atom by a ligand (e.g., hydroxamic acid), and occupancy of the S1 pocket with a hydrophobic group [53] [54] [55] [56] [57] . Another interaction often observed involved hydrogen bonding between an acceptor on the inhibitor and main chain NHs of amino acid residues flanking the catalytic site, specifically Leu-185 and Ala-186 (MMP-13 numbering). The close proximity of the latter two interaction sites led Robinson's group to consider lactams that could make both hydrogen bonddonating and -accepting contacts and, being cyclic, would possess the entropic advantage of ring constraint. Using a homology model of the catalytic domain of MMP-13 based on the X-ray structure of MMP-8 [58] , five-and six-membered ring lactams were examined to identify the position most favorable for attaching a ligand for the active site Zn atom [59] . Among the various possibilities, the pyrrolidin-5-one 10 bearing hydroxamate at the 2-position was especially attractive ( Table 1) . A pyrrolidinone template 11 was selected based on an analysis of hydrogen-bonding interactions made by known MMPIs and the vectors required for correct projection of established MMP binding groups (hydroxamate for Zn chelation, substituted aryl for occupation of the S1 site). The novel structure of 11-1, a 4-arylpyrrolidin-5-one-2-carboxylic acid hydroxyamide, represented a significant departure from those of the majority of reported MMPIs, showed modest to high selectivity for MMP-13 versus MMP-2, MMP-3, and MMP-9 ( Table 1) .
Although 11-1 was a potent and novel MMP-13 inhibitor 59], but epimerization of the relatively acidic C4 position under moderately basic conditions (e.g., alkoxide) limited the scope of chemistry that could be employed for the synthesis of analogues. An intriguing possibility for avoiding epimerization at C4 was to replace this center with a nitrogen atom giving the corresponding imidazolidinone, however, based on modeling studies using a homology model of MMP-13 [59] , it was clear that P1 groups would no longer be oriented correctly for occupancy of the S1 pocket due to the planar geometry of the cyclic urea function. Robinson et al. therefore considered compounds such as 12 ( Table 1) in which a methylene spacer was introduced to allow greater flexibility of the P1 side chain [60] . 12-1 exhibited potent activity against MMP-13 (IC 50 =3nM), the compound also displayed moderate potency against MMP-2 and MMP-9 but was significantly less active against MMP-1 and MMP-3. Indeed, modeling of 12-1 in the active site of MMP-13 showed that this molecule could attain a low energy conformation positioning the 4-fluorophenoxyphenyl group deep within the S1 pocket, while maintaining important contacts made by the hydroxamic acid and cis amide functions.
Recently, Natchus's group has been developing both succinamide and heterocyclic [61, 62] inhibitors, with a focus on understanding the structural modifications which might deliver the appropriate inhibitory profile, which would slow the progression of OA while minimizing or eliminating the occurrence of MSS. From this effort, a series of inhibitors based on an aminopyrrolidine scaffold was developed which displayed a wide range of enzyme profiles [63] . All compounds were derived from cis-4-hydroxy-Dproline (13) , and all of the substituted amines in 14 ( Table 1) appeared to be sensitive to modifications of the S1 portion of the molecule (R). This sensitivity was typified by amide 14-1 where longer-chain substituents increased the potency for MMP-13 and decreased the potency for MMP-1. This observation was supported by X-ray data which placed the alkoxyaryl group in the S1 pocket of the MMP enzymes. This pocket was very deep for most enzymes, but it was blocked by an arginine and a tyrosine residue in MMP-1 and -7, respectively [64] . The heterocyclic compounds in 15 and 16 ( Table 1 ) displayed inhibition profiles which closely mimicked those of the substituted amines. Compounds 15-1 exemplify the increase in selectivity for MMP-13 over MMP-1. The hydantoins shown in 16 presented potency profiles which were very similar to those seen with the heterocyclic amines in 15. Substitution of the hydantoin moiety played only a minor role in the overall potency of the compounds, as seen with 16-1, compounds 15-1, and 16-1 significantly inhibited joint damage.
Earlier work at P&GP and other laboratories [61, 62] had demonstrated that a central, heterocyclic ring could be effectively used in the design of potent MMPIs 17 ( Table 1) . Pikul et al. believed that an additional ring substituent capable of interacting with the S2 binding site could provide an opportunity to modify not only the potency, but also the selectivity of such inhibitors against various MMPs [65] . Modification of the P2 substituent could provide such selectivity due to the hydrophilic nature of the S2 site of MMP-1 containing Ser-222, as compared to the hydrophobic nature of the target enzymes MMP-13, which contained Ile-222. In an effort to provide a heterocyclic template capable of additional P2 binding interactions, they designed a new series of MMPIs based on a 1,5-piperazine/diazepine framework as represented by structure 18. In this method, compound 18-1 containing a tert-butyl P2 group was found to have 1 nM potency for MMP-2, -3, -8, -9, and subnanomolar potency for MMP-13.
From CGS-27023A, Nelson's group wished to use a benzodiazepine template 19 ( Table 1) as a framework for designing potent MMP inhibitors [66] . In their discovery, the biphenyl derivative 19-1 was the most potent in the series 19 with subnanomolar IC 50 for both MM-9 and MMP-13. Compound 19-1 was also the most selective member of the series with a ratio of the IC 50 values of MMP-1/MMP-13 = 132 and TACE/MMP-13 = 498.
The anthranilic acid scaffold as a template for hydroxamic acid based MMP and TACE inhibitors 20 ( Table 1) was recently reported by some research groups [40, 43, 45, 67, 68] . Crucial for potent enzyme inhibition in this system were (1) an ortho relationship between the hydroxamic acid and sulfonamide P1 group and (2) a substituent at the other position ortho to the P1 group. Incorporation of the required ortho substituent into a fused ring was proposed as an entry to a series 21, which could explore interactions of inhibitors with new regions of the enzymes through a rigid scaffold [69] , quinoline 21-1, with an IC 50 of 1 nM versus MMP-9 and MMP-13, was 1000-fold selective over MMP-1 and over 100-fold selective over TACE. Quinoline 21-1 was equipotent to CGS-27023A in both the bovine articular cartilage explant assay and the dialysis tubing implant assay. In the rat sponge-wrapped cartilage model 21-1 gave 44% inhibition of cartilage degradation at 50 mg/kg po bid, again equivalent to CGS-27023A at the same dose. Furthermore, replacement of the quinoline nucleus 21-1 with a heterobicyclic scaffold gave analogues 22 ( Table 1 ) comparable in activity to the quinolines against MMP-13, 9 and 1 but more potent versus TACE. Pyrazolopyridine 22-1, with the same pyridyl ether tail, had a very similar MMP selectivity profile to quinoline 21-1, with the advantage of increased selectivity (>1000-fold) over TACE. Hydroxamate 22-1 was also equipotent to CGS-27023A in the explant and in vivo assays.
The discovery and SAR of novel N-hydroxy--phenylsulfonylacetamide derivatives, which were potent, selective, and orally active MMPIs [70] have been disclosed recently by Aranapakam's group. In their research, a -sulfonylhydroxamic acid derivative 23 ( Table 1) , which was synthesized by Roche BioScience and was advanced to phase II clinical trials for OA, has been chosen as a lead compound. They found that the selectivity for MMP-13 vs MMP-1 in the SAR of molecules of general structure 24, could be achieved by varying the R1 substituent. When R 1 was equal to long-chain alkoxy groups, the selectivity for MMP-13 over MMP-1 improved. Aromatic sulfonyl compounds were more potent than aliphatic or heteroaromatic sulfonyl derivatives. Compounds disubstituted at R 2 and R 3 were more potent MMPIs than simple monosubstituted compounds (R 3 = H). To achieve in vivo activity, an aliphatic basic amine was essential. Compound 24-1 was one of the best inhibitors reported based upon in vivo activity in the spongewrapped cartilage model (69±5% inhibition @ 25 mg/kg, po) and the dialysis implant model (for the dextro-isomer: 69±4% inhibition, @ 25 mg/kg, po). In these assays, CGS-27023A showed 52±4% and 68±3% inhibition, respectively, when administered at 25 mg/kg, po.
Even though 24-1 [70] had an excellent oral bioavailability (81% in rat) and was active in vivo, it (a) suffered from moderate selectivity and (b) presented an asymmetric center. During Aranapakam's group preceding research, they showed that selectivity over MMP-1 could be achieved by having a suitable R1 substituent on the molecule 24-1 ( Table 1) . X-ray studies had shown that the R 1 substituents of related compounds occupied the S1 pocket of the enzymes [41, 46] . Hence, by having a proper R 1 substituent, selec-tivity could be achieved [71] . To solve the chirality problem, the general structure 24-1 was modified to a symmetrical molecule such as 25 (Table 1) where the molecule becomes achiral and R 1 can be modified to achieve the selectivity over MMP-1. Among the several compounds synthesized, derivative 25-1 turned out to be a potent, selective, and an orally active MMPIs in the clinically relevant advanced rabbit OA model.
From modeling the known scaffolds 26 [72] (Table 1) and examining their hydrogen bond network, Cherney's group hypothesized that sultam 27 [73] could be fashioned into a novel MMP-13 inhibitor. In doing so, the sultam sulfonyl was placed within hydrogen bond distance of the conserved leucine on the MMP backbone. To accommodate this hydrogen bond, the group connected to the nitrogen of the sultam (L-P1 ) would have a novel entry into the S1 pocket of the MMPs, compound 27-1 was found to be an active inhibitor (MMP-13 IC 50 =3 nM) with 300-fold selectivity over MMP-1 and good oral bioavailability (F = 43%) in mouse. An Xray crystal structure of 27-1 in MMP-13 indicated that the pro-(S) sultam sulfonyl was capable of a hydrogen bond to Leu-185.
Sequence analysis and a homology model of MMP-13 constructed from an MMP-1 X-ray crystal structure indicated that MMP-13 belonged to the set of MMPs that have a deep S1 pocket, X-ray crystal structures of both enzymes subsequently confirmed this [44] . Since MMP-1 had a shallow S1 pocket, obtaining selectivity over MMP-1 (and other shallow S1 pocket enzymes) was expected to be possible by increasing the size of the P1 substituent in the inhibitor. Furthermore, Reiter et al. reasoned that sterically hindering the hydroxamic acid would reduce metabolism of this functionality [18] . Their investigations showed that the metabolically more stable compounds 28 ( Table 1) could be obtained through a substituent on the sulfonamide nitrogen of CGS-27023A, by a monocyclic or bicyclic pyran ring adjacent to the hydroxamate group. The pyran analog 28-1, a potent MMP-13 inhibitor (IC 50 0.75 nM) spared MMP-1 (560-fold), did not display fibroplasias in a two-week rat toxicology study. However, after dosing for four to six weeks in OA patients, exposure related MSS was observed. These results led them to terminate the study of this series of compounds, and to conclude that inhibition of MMP-1 alone was not responsible for the MSS side effect that had been seen in humans with a variety of MMP inhibitors, and encouraged them to seek MMP-13 inhibitors that possessed higher degrees of selectivity over other MMPs.
Arylsulfonamido hydroxamic acid 29 [74] (Table 1) , which was recently reported by Rossello's group during their research on sulfonylated MMPIs, showed good selectivity for MMP-2 over MMP-1 and MMP-14. Compound 29 represented the first example of a new family of tertiary sulfonamides (the N-O-alkyl sulfonamides) possessing a small O-alkyl group on their sulfonamido nitrogen. In an effort to shift the activity and selectivity toward MMP-13 as target for OA, Rossello's group aimed to modify the arylsulfonyl moiety that interacted with the S1 subsite. The activesite structure of MMP-13 was well-known in the literature, because many X-ray crystallography and NMR studies had been reported on complexes of this enzyme with different inhibitors [41, 44, 75, 76] . Bearing in mind that the MMP-13 S1 subsite was an unusually large and deep pocket, they designed a series of N-isopropoxyarylsulfonamides 30 (Table 1) [77] that incorporated bulky and long P1 substituents, and beared different aryl substituents on the sulfonamidic portion. These compounds were assayed in vitro using recombinant MMPs, and the most promising scaffold was modified by introducing an alkyl group in the position relative to the hydroxamate, in order to increase its inhibitory activity. As expected, compound 30-1 ( Table 1) proved to be the best of the series exibiting a 6-fold increase in inhibitory potency against MMP-13 (IC 50 =3.0 nM) and a lower activity for MMP-1, MMP-14, and TACE. When tested in a porcine articular cartilage explant model in order to verify the activity of these inhibitors on collagen and aggrecan degradation occurring during OA, compound 30-1 was effective at 1 μM in blocking collagen degradation.
Carboxylic Acid-Based MMP-13 Inhibitors
The high potency of the majority of the published MMPIs has traditionally been associated with the presence of a hydroxamic acid functionality in the molecule [28] . The ability of the hydroxamate groups to efficiently complex the catalytic zinc and also to develop two hydrogen bonds to Glu-202 and Ala-165 [78] provided a major potency advantage over other ZBGs. However, PK challenges associated with the hydroxamic acid group prompted many research groups to look for alternative ZBGs [28] . Out of several groups explored, the carboxylic acid-based inhibitors have attracted considerable interest, leading to the discovery of several scaffolds ( Table 2) . While these compounds represented considerable progress in the design of carboxylate-based MMPIs, their relatively low potency has left plenty of room for improvement.
Recently significant interest has been directed toward selective MMP-13 inhibitors that contained a carboxylic acid moiety as a zinc binding element, and this effort was benchmarked by BAY-129566 ( Table 2 ) and disclosured by Warner-Lambert [79] , this compound contained a biaryl moiety that inserts into the P1 pocket of MMP enzymes, and effectively selected against shallow pocket enzymes such as MMP-1 and -7. So in 2001, Tullis et al. tried to design and target carboxylic acid inhibitors [80] that would specifically allow interactions with the S2 pocket of the enzyme, and minimize the high protein binding issues reported for BAY-129566 [81] , and followed this lead with to design and synthesize some substituted cyclohexylglycine analogues 31 ( Table 2 ) which exhibited selective inhibition of MMP-2 and MMP-13, while sparing MMP-1 and MMP-7, compound 31-1 exhibited low nanomolar potency for MMP-2 and MMP-13.
In 2001, Pikul et al. examined carboxylic acid-based inhibitors with the primary goal of improving their inhibitory potency [82] . They realized that additional binding interactions between the inhibitor and the target enzyme would have to be identified to compensate for the loss in potency observed with the hydroxamate to carboxylate switch. Using both molecular modeling and low resolution X-ray crystallographic data obtained for the complex of their model carboxylic acid 32 ( Table 2 ) with stromelysin, they decided to explore piperidine-based structures as represented by 33. The backbone was flexible enough for the carboxylic group to effectively complex with the catalytic zinc, yet the compound possessed the desired conformational stability due to the presence of a ring at the position to the carboxylic acid. This compound was also projected to have favorable binding interactions in the S2 pocket of stromelysin. Indeed, this design led to the discovery of a novel series of carboxylate-based inhibitors of MMPs with unprecedented potency and selectivity. Compound 33-1 containing a Bocprotected piperidine ring and the methoxybiphenylsulfonyl as a P1 group exhibited an inhibitory IC 50 value below 10 nM for MMP-2, -8, -9, and -13, and below 100 nM for stromelysin-1. This high level of potency against "desired MMPs" was also accompanied by rather limited binding to MMP-1 and MMP-7 (IC 50 = 1.37 μM and 3.66 μM, respectively), an important feature of the compound due to concerns about potential side effects of MSS.
In 2005, Wu et al. designed a selective, orally bioavailable MMP-13 inhibitor 34 [83] began with CL-82198 ( Table 2 ), a HTS hit that had an IC 50 of 3.2 μM against MMP-13 and was selective over MMP-1 and MMP-9. Structure-based drug design strategies [35] were employed firstly to append carboxylic acid as a Znchelating group to one end of the molecule, and then correctly position the benzofuran moiety of the P1 group, a biphenyl P1 linker was installed to rigidify the molecule, fill the hydrophobic S1 tunnel, and to -stack with HIS222. Thus, a series of rigid and potent inhibitors of MMP-13 against the highly homologous MMP-2 were obtained, exampled by compound 34-1 also had increased selectivity for MMP-13 over MMP-3 and MMP-7, and MMP-14.
Compound 35 ( Table 2) , which was recently disclosed by Wu et al., showed excellent selectivity for MMP-13 over MMP-1, MMP-9, MMP-14, Aggrecanase 1 (Agg1), and TACE [83] due to its long, rigid P1 group. However, compound 35 lacked selectivity against some other MMPs, including MMP-2, MMP-3, MMP-7, and MMP-8. In an effort to improve the selectivity of 35, available MMP X-ray data were examined and computer modeling analyses of MMP S1 subsites were performed. These studies indicated that the loop region of MMP-2 that formed its S1 pocket was two amino acids shorter than the analogous region in MMP-13. Thus, the S1 pocket of MMP-2 was constricted, relative to that of MMP-13. Structure-based design indicated that incorporating a substituent at the 4-position (R2) of the benzofuran would take advantage of this size difference and enhance selectivity. This structural analysis also indicated that if selectivity was optimized for MMP-13 over the closely related MMP-2, selectivity over MMP-3, -7, and -8 as well would be likely be achieved [84] . So in 2005, Li et al. reported their efforts to enhance the selectivity of these inhibitors 36 [85] for MMP-13 over MMP-2, by extending the SAR of this scaffold to compounds bearing multiple substituents on the benzofuran P1 ring system, one of the reprented compound 36-1, bearing a 4-methoxy group on the benzofuran, was most potent against MMP-13.
However, further development of compound 36-1 [85] was precluded by poor oral bioavailability, perhaps due to solubility and permeability issues. So in 2005, Hu et al. reported on the modification of the amide bond of the P1 moiety of 36-1 as a means of improving PK properties with minimal structural change [86] . As MMP-2 was highly homologous to MMP-13 in and around the S1 pocket, it was hoped that compounds that demonstrated selectivity over MMP-2 would also possess enhanced levels of selectivity over a wide variety of other MMPs. Since the loop region of MMP-2 (e.g., PDB code 1QIB) that formed its S1 pocket was two amino acids shorter than the analogous region in MMP-13 (e.g., PDB code 830c), the S1 pocket of MMP-2 was constricted relative to that of MMP-13 [83] . Molecular modeling suggested that incorporating a substituent at the 4-position of the benzofuran would take advantage of the difference in size between the S1 pockets of MMP-2 and MMP-13, and enhance selectivity. Therefore, compounds 37 ( Table 2 ) with an ether linkage to the benzofuran were synthesized. Compound (R) 37-1 against a variety of MMPs showed moderate selectivity against MMP-2, -3, and -8, and greater than 500-fold selectivity over MMP-1, -7, -9, -14, and TACE ( Table 2) . Ether (R) 37-1 was further tested both in vivo and orally in male SpragueDawley rats. This compound demonstrated in vivo low clearance (5.2 mL/min/kg at 2 mg/kg), compound (R) 37-1 was also 100% bioavailable when dosed orally at 20 mg/kg (T 1/2 = 197 min, C max = 8.3 μg/mL, and AUC = 65.7 h*μg/mL). A 20 mg/kg oral dose maintained plasma levels at >1000 ng/mL for l2 h. Because of its excellent potency and selectivity for MMP-13 and excellent oral bioavailability, compound (R) 37-1 was further evaluated in a bovine cartilage explant assay and demonstrated >50% inhibition of collagen degradation at a concentration of 10 ng/mL. Previously Li et al. reported that the 4-methoxy substituent of compound 38 ( Table 2) clashed with Thr229 of MMP-2 in the S1 pocket while the bromine atom at C5 help constrain the mobility of the methoxy group [85] . No such steric clash existed for these substituents within the larger S1 pocket of MMP-13. In 2009, Hu's group reported that bulky or rigid functional groups at the C4-position, in the absence of a C5 group, afforded analogs 39 ( Table  2) with good selectivity over MMP-2 while retaining excellent MMP-13 activity [87] . Extra size and flexibility of the S1 pocket allowed MMP-13 to accommodate a larger group at the C4-position of the benzofuran moiety. Since MMP-2 was one of the most homologous enzymes to MMP-13, compounds with selectivity over MMP-2 might achieve broader selectivities over other MMPs. As exemplified by 39-1, was more than 145-fold selective over the MMPs screened and was active in the cartilage degradation assay down to 0.1 μM.
The inhibitory potency of carboxylic acid MMP-13 inhibitors benefit from additional hydrophobic contacts with the S1 region, however, many of these lipophilic carboxylates are completely inactivated in the presence of serum proteins, such as bovine serum albumin (BSA), as a result of both high lipophilicity and anionic character [88] . Modification of the side chain to the piperidine carbamate yielded orally active BOC-piperidinyl glycine derivative 40 ( Table 2) , which was less affected by BSA. In 2009, Monovich et al. reported the optimization of 40, leading to the discovery of potent, orally active, nonhydroxamic acid MMP-13 inhibitors 41 lacking sheddase and MMP-1 activities [27] . Compound 41-1 was a subnanomolar inhibitor of MMP-13 (IC 50 value 0.5 nM and Ki of 0.19 nM) having no activity against MMP-1 or TACE (IC 50 of >10000 nM). Furthermore, in a rat model of MMP-13-induced cartilage degradation, 41-1 significantly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition) and at 10 mg/kg (40% inhibition). This was the first time that carboxylic acid based MMPIs had been shown to be equipotent to hydroxamic acid based inhibitors in models of cartilage protection.
Phosphorous-Based MMP-13 Inhibitors
Despite the potency disadvantage, other classes of inhibitors may offer advantages of their own. For example, phosphinate-based inhibitors may possess useful properties deriving from their capacity to accommodate side chains that bind in pockets on both sides of an enzyme's catalytic residues. Given that the binding pockets of related enzymes would be similar but not identical, binding of an inhibitor into more pockets should allow for the identification of compounds more selective for a specific enzyme. In addition, the binding energy gained through the interaction with additional pockets may allow the apparent inherent potency disadvantage of phosphinate-based inhibitors to be overcome.
Earlier work by Reiter's group demonstrated that the S1 region of MMP-1 could be effectively spanned with a benzyl group as in phosphinate 42 ( Table 3) which displayed an IC 50 of 2100±790 nM. Computational studies with this compound and a homology model of MMP-1 (built from an X-ray crystal structure of MMP-8) revealed that in a phosphinate with a benzyl group spanning the S1 region, a carboxamido group was not likely to be a suitable linker for directing a substituent into the S2 pocket. The amide functionality of 42 extended beyond the S2 pocket and was torsionally too rigid to allow a substituent thereon to reach the S2 pocket. Modeling indicated that excision of the carboxamide linker of 42 might allow the terminal phenyl residue to occupy the S2 pocket. They therefore sought to synthesize 43 ( Table 3 ) as a probe of this hypothesis [89] . The most potent MMP-13 inhibitors 43-1, which contained phenethyl side chains, when dosed in vivo in rats, displayed good PK with low clearance (12 mL/min/kg), a small steady state volume of distribution (0.2 L/kg) and a terminal half-life of 2.3 h. When dosed orally, the compound was not detected in the plasma. It was presumed that the lack of compound in the plasma was due to poor absorption, which was likely attributed to the charged nature of the compound at physiological pH.
In contrast to the considerable published SAR for P1 substitution of MMP-13 inhibitors [28, 31, 90] , little was known about the S2 pocket of MMPs [91, 92] . From a lead compound 43-1 ( Table  3 ), Reiter's group reported the results of their studies in which they have varied the P2 and P1 substituents of 44 seeking potent and selective MMP-13 inhibitors [93] . As a result, they chose to initially survey the effect of fluoro, methyl and methoxy groups at the 2-, 3-and 4-positions of the terminal P2 benzyl group. Compound 44-1, displayed excellent potency (MMP-13 IC 50 4.5 nM) and high selectivity versus MMP-1 (270-fold). 
-Fluorinated Ketones-Based MMP-13 Inhibitors
-Fluorinated ketones, binding in their hydrated form, have been shown to be inhibitors of metalloproteases such as carboxypeptidase A [94] , angiotensin converting enzyme [95] , metallo--lactamase [96] , and membrane-bound amino peptidase [97] . Being transition state mimics, -fluorinated ketones can readily bind in a substrate-like fashion in pockets on both side of an enzyme's catalytic residues. In this respect -fluorinated ketones resemble phosphinic acid-based inhibitors. That they are both monodentate ligands for the active site zinc is another similarity observed in the available crystal structures [78] , however, a significant difference between them is their pK a 's. Phosphinic acids will be nearly completely deprotonated at physiological pH and hydrated -fluorinated ketones will be substantially uncharged. This difference may translate into better absorption for a -fluorinated ketone-based inhibitor over a phosphinate-based compound of otherwise similar structure.
The above aspects of -fluorinated ketone-based inhibitors combined with recent finding by Reiter's group that phosphinate 45 ( Table 4 ) was a potent inhibitor of MMP-13 (IC 50 : 14 nM) [89] led them to prepare 46 [98] , so substrate-like difluoroketones had been prepared as potential inhibitors of MMP-13. The more potent activity of intermediate 46-1 illustrated that hydrated ketones can be used to inhibit MMP-13.
Thiol-Based MMP-13 Inhibitors
MMP-13 inhibitors that utilize thiol ZBGs have been synthesized and demonstrate, in some cases, inhibition at sub-nanomolar concentrations. Thiol-based MMP-13 inhibitors have been of interest due to the apparent thiophilicity of the zinc (II) ion in a number of proteins. Zinc is found coordinated by Cys residues in many proteins including 'zinc fingers', liver alcohol dehydrogenase (LADH), and metallothioneins [99] . Greater interest in thiol ZBGs was sparked from the discovery of the 'cysteine switch' selfinhibitory mechanism of MMPs (vide supra) [100] .
During the research for selective MMP-13 inhibitors, Freskos et al. found a simple sulfone hydroxamate 47 ( Table 5) showed modest selectivity for MMP-13 over MMP-1, when they changed the chelator from a hydroxamate to a thiol they were surprised that the potency for MMP-13 was almost identical [101] , also noteworthy was the inherently high selectivity of these thiol sulfones, selectivity in hydroxamic acid based chelators was achieved by placing large hydrophobic groups in P1 . In fact thiol 48-1 was some of the most potent and selective MMPIs yet reported, especially noteworthy was their lack of chirality and relative simplicity.
During the SAR optimization process Freskos et al. found that substitution and to the thiol 49 ( Table 5 ) was tolerated while substitution was detrimental to potency, they were curious to see if a cyclic thiol analog 50 [102] would maintain high potency against MMP-13 and MMP-8 while eliminating MMP-1 activity.
Compound 50-1 was selective for MMP-13 and MMP-8 over MMP-1, and this selectivity was due in large part to an Arg in place of Leu 213 in MMP-1, which resulted in a more shallow S1 .
Pyrimidinetrione-Based MMP-13 Inhibitors
Barbituric acid based inhibitors, as exemplified by inhibitor 51 ( Table 6) , appear to provide an interesting alternative to hydroxamic acid based inhibitors. Though its potency against MMP-13 has not been reported, compound 51 was reported to be an inhibitor of MMP-8 (IC 50 = 107 nM), and MMP-9 (IC 50 = 20 nM). Barbituric acid could in principle bind to a zinc atom via interactions with either a carbonyl oxygen, a ring nitrogen or a combination of the two atoms. Based on the understanding of the barbiturate-zinc interaction, Kim et al. sought to apply structure-based design to produce potent barbiturate containing inhibitors 52 ( Table 6 ) of this enzyme [103] , the spiro-barbiturate 52-1 had a potency and improved MMP-13 selectivity
In order to discover therapeutically useful MMP-13 inhibitors involved identifying compounds that possess a ZBG other than the ubiquitous, and generally metabolically labile, hydroxamic acid [19] , file screening by Reiter's group revealed pyrimidinetrione 53 ( Table 6 ) as a weak MMP-13 inhibitor, molecular modeling suggested that the pendant aryl ether of 53 would occupy the S1 pocket, while the methyl group would project into a largely solvent exposed region. Incorporation of a biaryl ether moiety at the C-5 position of the pyrimidinetrione ring 54 ( Table 6 ) resulted in a dramatic enhancement of MMP-13 potency. Protein crystallography revealed that this moiety binded in the S1 pocket of the enzyme. Optimization of the C-4 substituent of the terminal aromatic ring led to oxadiazole 54-1, potent MMP-13 inhibition with a >200-fold selectivity over MMP-14. In vivo in rats 54-1 was found to have a moderate half-life (t 1/2 = 4.0 h), low clearance (0.63 mL/min/kg), and a low volume of distribution (0.20 L/kg). Oral absorption was excellent (~100%).
Subcequently, in pursuing inhibitors 55 ( Table 6) containing P1 terminal amides, Reiter's group observed that reasonable levels of selectivity (>50-fold) over MMPs -2, -8, and -12 could be obtained with certain substitution patterns [104] . Through this strategy, the 4-cyano derivative 55-1 showed excellent selectivity profile (MMP-1: 2400-fold, MMP-3: 17,000-fold, MMP-9: 540-fold, and MMP-14: 540-fold) also displayed excellent PK (Clp 0.63 mL/min/kg, Vdss 0.34 L/kg, t 1/2 6.9 h) in rats. 55-1 was examined in the rat fibroplasia model, a surrogate for producing MSS in humans, no fibroplasia was observed.
In 2007, during the explorations in the pyrimidinetrione series 56 ( Table 6 ) of MMP-13 inhibitors, Reiter's group discovered that a series of spiro-fused compounds 57 [105] were potent and selective inhibitiors of MMP-13. Greater than 100-fold selectivity versus other MMP family members was achieved by incorporation of an extended aryl-heteroaryl P1 group. When dosed as the sodium salt, these compounds displayed excellent oral absorption and PK properties. Among these, 57-1 was found to have an excellent PK profile (Clp 3.9 mL/min/kg, V dss 1.3 L/kg, t 1/2 4.5 h). Compound 57-1 was very effective at preventing the MMP-13 induced in vitro degradation of bovine nasal cartilage (as measured by hydroxyproline release) with an IC 50 of 0.12 nM. Compound 57-1 also performed very well in the in vivo hamster model of direct intraarticular injection of MMP-13 into the knee joint (>80% inhibition at 10 mg/kg po). 57-1 showed no acute toxicity despite very high doses for a 14-day rat fibroplasia study, a surrogate for the production of MSS in humans.
Non-Zinc-Chelating-Based MMP-13 Inhibitors
MMPs have a conserved active site motif, where a tris(histidine)-bound zinc(II) acts as the catalytic site for substrate hydrolysis. Historically, most MMPIs gained affinity through interacting with the catalytic zinc via a chelating moiety (e.g., hydroxamic acid) and by positioning hydrophobic functionality in the S1 pocket [31, 83, 85] . The S1 pocket is in part formed by the selectivity loop which varied in length and amino acid sequence for different MMP isoforms. These S1 differenced between MMP family members have been utilized to design MMP inhibitors with different selectivity profiles [106] . MMP-13 has an additional region for inhibitor binding that has not been observed in other MMP isoforms. This region is referred to as the S1 * pocket. At present, the most potent and selective MMP-13 inhibitors occupy both the S1 and S1 * pockets [84, [107] [108] [109] . The potency provided by binding to the S1 and S1 * sites reduces the need for inhibitors to require a Zn binding group.
In 2008, HTS of compound collection by Li et al. provided, in addition to all of the broad-spectrum MMP inhibitors, a unique hit [110] , thiazolopyrimidinedione 58 (Table 7) , which possessed an astounding selectivity for MMP-13 versus other MMP isoforms. Cocrystallization of 58 with the MMP-13-CD (catalytic domain) revealed an unexpected nonzinc-binding mode: instead of binding to the Zn 2+ cation, 58 binded deep within the S1 -specificity loop of the protein and extended past this pocket out toward the bulk solvent. S1 was the first specificity subunit from the catalytic site (Zn 2+ in this case) toward the N terminus and S1 was the first specificity subunit from the catalytic site toward the C terminus. The MMP catalytic domain consisted of a five-stranded -sheet and 3--helices, with the catalytic site defined by -strand IV and the central helix, which imparted significant structural differences or MMP isoforms. The S1 -specificity pocket in MMP-13 was unusually large, open channel, nearly twice the size as that found in MMP-1, which may explain the high degree of specificity of 58. However, 58 was an ester, metabolizing readily in the body, and the corresponding acid was inactive in MMP-binding assays. Using computer-aided drug design (CADD) and methodical SAR studies, Li et al. obtained pyrido [3,4-d] pyrimidin-4-ones 59 (Table 7) , that were potent and specific MMP-13 inhibitors, some of which were orally bioavailable. 59-1 was a potent MMP-13 inhibitor with an IC 50 of 6.72 nM in the MMP-13 CD assay but did not inhibit all other MMP isozymes tested, including MMP-1, MMP-2, MMP-3-CD, MMP-7, MMP-8-CD, MMP-9, MMP-12, MMP-14-CD, and MMP-17-CD. 59-1 had a moderate clearance and moderate volume distribution in rats, its half-life was 3.9 h, F% of 73%, and AUC (po) of 13400 ng h -1 mL -1 . 59-1 effectively prevented cartilage damage in animal models of OA without inducing musculoskeletal side effects when given at extremely high doses to rats.
In 2009, through a Graffinity SPR microarray screening campaign, Heim-Riether et al. identified hit structure 60 ( Table 7) that was subsequently determined to have an IC 50 of 430 nM against MMP-13 [111] . Compound 60 attracted their attention since it did not contain an obvious Zn-chelating group and showed selectivity over MMP-14-the one isoform postulated to play a role in MSS [112] . With the aid of protein co-crystal structural information, they observed that compound 60 didnot fill the S1 pocket. The phenyl ring occupied only the entrance to the S1 pocket, thus providing the opportunity to grow into the S1 pocket to improve potency against MMP-13 and the overall selectivity profile against additional MMP isoforms. Potency and selectivity of 61 were improved by extending the hit structure out from the active site into the S1 pocket, with by adding an aryl group through two different linking functionalities. Dimethylpyrazole 61-1, became the most potent and selective MMP-13 inhibitor of the series.
Phenyl dicarboxamide 62 ( Table 7) , which was discovered by HTS, showed modest inhibitory activity for MMP-13/CD (IC50 = 1.35 μM) and demonstrated high selectivity against a range of MMPs (IC50 >100 lM, MMP-1, 2, 3, 7, 9, 14) . The discovery of compound 62 offered the opportunity to merge activity-based learnings from these series with a simplified core ring template that could provide improved physiochemical properties. So in 2010, Schnute et al. described the optimization of the monocyclic hit 62 to provide highly potent, selective, and orally-bioavailable MMP-13 inhibitors 63 ( Table 7 ) that demonstrated cartilage protection in preclinical OA animal models [113] . Compound 63-1 demonstrated potent inhibition of full length MMP-13 (Ki = 4.4 nM) and exhibited exquisite selectivity (Ki >25 μM) against a set of 13 MMP enzymes, TACE, ADAMTS-4, and ADAMTS-5. Compound 63-1 also inhibited cytokine stimulated CII degradation from human articular cartilage in a dose dependent manner (IC 50 = 2 μM). Excellent oral bioavailability was also observed in the rat (F = 100%, 1 mg/kg dose) with low clearance (14 mL/min/kg, T1/2 Eff = 2.8 h). The co-crystal structure of compound 63-1 and the catalytic domain of MMP-13 showed that the cyclohexane ring protruded beneath the S1 specificity loop with the terminal carboxylic acid contacting Lys-140 and were not ligands for the catalytic zinc atom. The methyl substituent on the pyridine ring which significantly improved MMP-13 inhibition was found to fill a hydrophobic region in the southern portion of the S1 pocket. The methyl group buttressed against Pro-255 further enforcing the orientation of the tetrazole substituent through the tunnel region beneath the specificity loop. Compound 63-1 demonstrated reduction of cartilage degradation biomarker levels associated with cartilage protection in a preclinical rat OA model.
DUAL INHIBITORS OF MMP-13 AND AGGRECANASE
The pathogenesis of OA can be attributed to multiple factors that affect the degeneration of proteoglycan and disruption of the CII network in cartilage [114] . These critical components of cartilage maintain its structural integrity and impart mechanical properties associated with normal joints. Aggrecan monomers interact with hyaluronic acid and link proteins to form high molecular weight networks with ordered hydration that provides cartilage with resilience and compressibility. CII is a triple-helical protein that forms a highly organized three-dimensional structure responsible for tissue stiffness and integrity. Both aggrecan and CII can be degraded by proteolytic enzymes that have elevated expression in OA joints. Aggrecanase refers to a collection of proteases that cleave aggrecan and belong to the ADAMTS family of zinc containing metalloproteases [115] . On the other hand, MMP-13 is particularly efficient at cleaving CII, its expression is regulated by proinflammatory mediators and elevated in OA joints [116] . So inhibition of the enzymes that mediate cartilage catabolism (aggrecanases and MMP-13) is a strategy for developing disease modifying therapies for OA.
Recently, in order to protect both the aggrecan and CII components of cartilage, Noe's group sought to discover compounds that possessed inhibitory activity versus both MMP-13 and aggrecanase [117] . Previous MMP and TACE programs at Pfizer led to the discovery of pipecolic acid based inhibitors [118] such as 64 (Table 8) , Table 7 these compounds generally lacked potent aggrecanase inhibition and suffered from metabolic lability of the hydroxamic acid moiety. Noe's group envisioned the series represented by 65 [117] to be superior due to increased polarity, steric encumbrance of the hydroxamic acid moiety and proximity of the polar hydroxyl group to the hydroxamate functionality [71] . Compound 65-1 was a potent inhibitor of both MMP-13 and aggrecanase. The PK parameters of compound 65-1 in rat showed low clearance (Clp=9.0mL/min/kg), and a long t 1/2 (5 h). Unfortunately, oral bioavailability was poor (7% when dosed as a suspension in 0.5% aqueous methylcellulose) despite good P app values obtained in CACO-2 experiments (P app A:B=30 10 -6 ; B:A=15 10 -6 ). So 65-1 could provide a useful starting point for the discovery of agents for the treatment of osteoarthritis.
Pipecolic acid based inhibitors 66 ( Table 8) , which was discovered by MMP and TACE programs at Pfizer [118] , exhibited the most potent inhibition of both MMP-13 and aggrecanase activities. However, compounds from this series generally exhibited poor PK properties due to high metabolic clearance. Therefore, Noe's group incorporated additional substituents at the piperidine 3-position of 67 (Table 8) , with the intent of improving the metabolic stability of the hydroxamate group [119] , presumably by increasing steric hindrance around the metabolically labile hydroxamic acid, thereby limiting access to metabolic enzymes. Potency versus aggrecanase was optimized by modification of the benzyloxyarylsulfonamide group. This modification also resulted in dramatic improvement of aggrecanase activity with a slight reduction in selectivity versus MMP-1. The 2,4-disubstituted compounds provided the best potency, with the 2-chloro-4-fluoro analog 67-1 displaying nanomolar inhibitory activity and >100 selectivity for MMP-13 and aggrecanase over MMP-1.
Recently, the presence of a hydroxamic acid presented significant challenges for the optimization of PK properties necessary for an effective oral therapy. The hydroxamic acid group was particularly prone to hydrolysis, reduction, and glucuronidation [71] . As part of the strategy to reduce the metabolic lability of lead aggrecanase series 67 [119] , Noe's group designed another series of 3-hydroxy-3-methylpipecolic hydroxamate 68 ( Table 8 ) with similar functional activity but greatly improved metabolic stability and bioavailability [120] , based on the observation of increased aggrecanase activity with substitution at the 3-position of the piperidine ring. Potency versus aggrecanase was optimized by modification of the benzyloxyarylsulfonamide group that binds in the S1 pocket. The 2,4-disubstituted compounds provided the best aggrecanase potency, with the 2-chloro-4-fluoro analogue 68-1 providing low nanomolar inhibitory activity for aggrecanase and MMP-13, and > 100 selectivity over MMP-1. Compound 68-1 showed moderate clearance in rat (Clp = 13 mL min -1 kg -1 , t 1/2 = 2 h) and dog (Clp = 11 mL min -1 kg -1 , t 1/2 = 4.6 h) that was consistent with predicted clearance based on incubations with rat and dog hepatocytes (ER = 0.20 and 0.28, respectively). The markedly lower metabolic clearance with this compound was attributed to the presence of the polar hydroxyl group, as well as equivalent steric hindrance proximal to the metabolically labile hydroxamic acid. It was also possible that intramolecular hydrogen bonding between the hydroxyl group and the hydroxamic acid influenced absorption and clearance. When dosed orally in hamsters, 68-1 exhibited potent inhibition of IL-1 induced aggrecan degradation (ED 50 = 4.6 mg kg -1 ) and MMP-13 induced collagen degradation (ED 50 = 13 mg/kg) in hamster knee joints.
CLINICAL TRIALS

Examples of MMPIs in Clinical Trials for Osteoarthritis
As MMPs have an important role in ECM turnover many groups have investigated if blocking MMPs will prevent tissue destruction. Early challenges involved the development of MMPIs with high potency that would be orally available, avoiding modification or destruction within the gut. Some of these compounds were found to cause musculoskeletal pain and tendonitis was identified as a reversible side-effect in treated patients [34] . These effects commenced in the small joints of the hand and upper limbs and the symptoms were time and dose dependent but reversible.
Such symptoms were seen with a compound Ro 31-9790 (Roche) (Fig. 5) and this led to its withdrawal from development as an arthritis treatment. New compounds are now screened in rodent models and compounds that cause musculoskeletal side effects are discarded at an early stage of development. The cause of these side effects is not known and Peterson [34] has emphasised the need to estimate the dose required for efficacy and that producing toxicity during the development of each new inhibitor. MMPs are involved in many physiological processes that include the activation and/or release of cytokines and growth factors from the ECM [121] . Inhibition of such MMPs could block processes that in normal tissues maintain the precise balance between synthetic and degradative pathways.
Novartis (formerly Ciba-Geigy) have described an orally active hydroxamate MMP inhibitor, CGS-27023A (Fig. 3) . This broad spectrum inhibitor with nanomolar Ki against MMP-1, -2, -3, -9, -12 and -13 was chondroprotective in both the rabbit menisectomy model of OA and the guinea pig model of spontaneous OA [37] . Phase I clinical trials of CGS-27023A in humans were halted due to musculoskeletal side effects [17] .
Trocade (Ro 32-3555) (Fig. 5) , a selective collagenase inhibitor has a low nanomolar inhibition constant (Ki) against MMP-1, -8 and -13 with approximately 10-to 100-fold lower potency against MMP-2, -3 and -9. It blocks IL-1 -induced collagen release from cartilage explants and, in vivo, prevented cartilage degradation in a rat granuloma model, a P. acnes-induced rat arthritis model and OA model using the SRT/ORT mouse [122] . A large scale trial of 1000 RA patients treated with Trocade was terminated after 1 year because of a lack of efficacy, although the drug was reported to be well tolerated in patients [123] .
Tanomastat (BAY 12-9566) (Fig. 5) , a synthetic MMP inhibitor that targets MMP-3, -2, -8, -9 and -13 with low activity against MMP-1 is effective in guinea pig and canine models of OA and was proposed for the treatment of OA. BAY 12-9566 was given to 300 OA patients for 3 months and no musculoskeletal side effects were reported, and the drug could be detected in the cartilage of treated patients undergoing joint replacement [124] . However, this compound was withdrawn from patient phase III OA trials following negative results in cancer patients.
The antibiotic doxycycline is known to inhibit MMPs, albeit quite weakly, and some recent derivatives can be shown to inhibit MMPs but have no antibiotic activity. These compounds are currently licensed for the treatment of periodontal disease and have been proposed as a treatment to prevent cartilage damage in the arthritides [125] . Periostat (CollaGenex Pharmaceuticals, Inc.) (Fig.  5) , a sub-antimicrobial dose of doxycycline, is currently the only US Food and Drug Administration (FDA) approved MMP inhibitor and is licensed for the treatment of periodontal disease. These compounds are effective in animal models [126] , and results from a trial of 430 OA patients [127,128. ] randomly assigned to receive either doxycycline or placebo treatment look to be promising. When the X-rays of the two groups were compared at 30 months the initial results suggest that protection of the joint was seen in the treated patients. Now synthetic MMP inhibitors were initially studied for their ability to prevent joint destruction in animal models of arthritis. Sabatini et al. [129] showed that S-34291 (Fig. 5) , a wide-spectrum MMP inhibitor with a preferential effect on MMP-13 as compared with MMP-1, prevented the loss of cartilage ex vivo and in a guinea pig model of OA.
A number of companies are developing MMP-13 inhibitors such as CP-544439 (Pfizer) (Fig. 1) and WAY-170523 (Wyeth Research) (Fig. 5) , which were taken to phase II clinical trials. Other compounds such as CPA-926 (developed by Kureha and Sanyo for the treatment of OA) (Fig. 5) and the broad spectrum MMP inhibitor ONO-4817 (developed by ONO) (Fig. 5) have also been used in phase II or I clinical trials, respectively [34] . Pharmacia, Wyeth and Proctor & Gamble have all reported on the preclinical evaluation of MMP inhibitors for the treatment of arthritis [130] .
In selectivity assays using catalytic domains of human MMPs performed by Baragi et al., another selective MMP-13 inhibitor ALS 1-0635 (Alantos), potently inhibited articular cartilage degradation in vitro and also in the rat monosodium iodoacetate-induced OA. Interestingly, this agent exerted protective effects without signs of musculoskeletal toxicity in rats with surgically-induced medial meniscus tear [131] .
Further studies are required to demonstrate the effectiveness of MMP inhibitors in the prevention of joint destruction. The clinical evaluation of these drugs is difficult and expensive as long trials have to be conducted. Radiographs are still the most reliable measure of joint damage but any change in joint damage is impossible to detect over short periods of time. Whilst some progress has been made with the use of magnetic resonance imaging (MRI) to image joints this technology is still to be proven and routine centres do not have access to a validated method for quantitation.
Reason for the Failure of Many MMP-13 Inhibitors
A variety of explanations have been offered to explain why many of the metalloproteinase inhibitors have been unsuccessful in clinical trials in patients with joint diseases and cancer [132] .
Firstly, there is no doubt that MMPs are present and active in joint diseases, but if compounds are unable to penetrate the cartilage/bone/synovial interface they would clearly be ineffective.
Secondly, whether the MSS effects that have plagued many MMPIs are due to the inhibition of a particular MMP, or a group of MMPs is unclear. Early inhibitors were originally screened against a limited set of available MMPs and so may not inhibit some that have subsequently been discovered and which play important roles. It has been postulated by some that the inhibition of MMP-1 is responsible for MSS due to its involvement in normal tissue remodeling and its ubiquitous expression [133] . Others have proposed that MSS is related to the inhibition of MMP-14, since MMP-14 knockout mice display a phenotype similar to MSS [134] . The inhibition of sheddases like TACE has also been suggested as a root cause for MSS [24] . The quest to fulfill the vast therapeutic potential of MMP inhibitors therefore requires the investigation of novel inhibitor scaffolds with a range of MMP inhibition selectivity profiles in order to develop an optimal, clinically efficacious inhibitor.
Thirdly, clinical trials of early MMPIs indicated poor bioavailability and efficacy, largely due to the broad-spectrum inhibition of MMPs. Most MMPIs consist of a ZBG capable of binding the catalytic Zn 2+ ion, at least one side chain to interact with the enzyme sub-sites, and either a peptidomimetic or non-peptidomimetic backbone that interacts with the protein [135, 136] . However, the ability to bind other metal ions meant that many of the early MMPIs proved unsuccessful in clinical trials [84] . Consequently, recent attempts at developing MMPIs have focused on using alternative, less potent ZBGs [135, 137] , and developing sub-type selective MMPIs based on MMP structure. However, achieving sub-type specific inhibition has proven quite difficult, due to the structural similarity of many MMPs [138] . These developments in MMPI design have recently been reviewed by Fisher and Mobashery [139] .
Fourthly, the failure of many MMPIs is the inaccurate estimation of dosage to prevent drug toxicity, which often manifests as MSS effects, such as joint pain and stiffness, oedema, reduced mobility and skin discolouration [34, [140] [141] [142] . In some clinical trials, significant clinical efficacy was not able to be determined due to dose-limiting toxicity [143] . Several hypotheses attempting to explain MSS have been proposed, but the exact mechanism remains elusive. Recent investigation indicates that MSS associated with MMPI administration may not be due to MMP inhibition per se, but actually the result of off-target metal chelation [144] . A recently described specific inhibitor of MMP-13 appears to bind within the catalytic pocket of MMP-13 without chelating the zinc ion, and has proven to be chondroprotective in animal models of OA, without any musculoskeletal aberrations [108] . It remains to be seen whether the same level of success observed in animal models will be transferrable to humans, but these pre-clinical results provide promising evidence that this new class of MMPI is a potential candidate for MMP-13 inhibition and treatment of OA.
There are a number of challenges in the clinical evaluation of these compounds. Essentially, the task is to measure structural damage, and whether or not the chosen MMP inhibitor can significantly prevent it. Radiographic imaging is currently the only validated method for assessing structural damage. For OA, radiographic outcome may be measured using the 1995 OARS atlas for joint space narrowing as a measure of cartilage loss and osteophytes of the knees, and joint space narrowing, osteophytes, and erosions for affected joints of the hands. Rates of progression vary greatly between patients, which means that large patient numbers are needed, possibly in excess of 200 for each arm of the trial. In addition, to evaluate the effectiveness of an MMP inhibitor over time, the expected rate of progression has to be estimated in order to assess the sample size as well as the target profile for the inhibitor to prevent progression.
A realistic study length is also needed, over which significant radiographic progression is expected to occur. Currently, the minimum required duration of pivotal trials for a label claim of prevention of structural damage is two years for OA. Logistically, these studies require a large number of trial centres and, crucially for the assessment of radiographic outcome, the equipment and techniques for obtaining them must be standardised. Efficacy of the MMPIs depends on comparing the follow up and baseline radiographs in a blinded manner. This is best achieved by using a single central facility with a team of validated readers to ensure consistency of radiographic scoring and minimal variability, especially as the expected progression of joint damage over one or two years may be minimal. At this point it would be pertinent to mention MRI as a promising replacement for radiographs. The prospect is that MRI may be more sensitive over time to continuing joint damage and may reduce the duration of trials and the patient numbers required. However, MRI facilities are not always readily available and the technique is not, as yet, validated.
CONCLUSIONS ABOUT THE FUTURES OF SELECTIVE MMP-13 INHIBITORS
Inhibition of cartilage collagen destruction still remains an important and viable target to prevent joint damage in OA disease. Although the trials of broad MMPs inhibitors in patients have been disappointing new selective MMP-13 inhibitors are still under development and these may overcome some of the problems of both delivery and side effects. A key to future success is to identify the specific enzymes that are responsible for MSS. This will allow highly specific MMP-13 inhibitors that potentially reduce side effects. It should now be possible to screen all new inhibitors across the MMP family to ensure specificity.
It is interesting that when patients are treated with the new anticytokine therapies a greater protection of the joint is obtained when this is combined with more conventional treatments. It is likely that blocking of MMP-13 will be more effective if combined with treatments that target earlier steps in inflammation. Furthermore, as noted above, MMP-13 is not alone in being implicated in joint disease. Aggrecanase is believed to cleave aggrecan and belong to the ADAMTS family of zinc containing metalloproteases. It may be necessary to combine proteinase inhibitors, either in sequence or with other agents that hit other specific steps in the pathogenesis, before the chronic cycle of joint destruction found in these diseases can be broken. 10KJA360039). 
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